In 2022, Jia et al. reported an advanced NSCLC patient with EGFR ex20ins benefited from high-dose furmonertinib (160 mg/day) after progression from mobocertinib, with a PFS of 10 months (Jia et al., 2022) (Table 2). Here, EGFR is linked to non-small cell lung carcinoma.